Shares of Moderna Surged Thanks to Vaccine Trial

An American company from Massachusetts reported the news that helped to boost its shares. According to Moderna, early-stage human trial for a coronavirus vaccine produced COVID-19 antibodies in all participants. Notably, 45 people took part in this process. The company’s shares jumped more than 17%.

Participants received two doses of the potential vaccine via intramuscular injection approximately 28 apart. According to the company, the vaccine also produced neutralizing antibodies against the COVID-19 in at least eight participants.

It is worth mentioning that neutralizing antibodies appear to be important when it comes to acquiring protection.

Moderna and coronavirus vaccine

Notably, scientists hope the antibodies provide some degree of protection against getting COVID-19. However, they can not say for sure since it has not been studied and it will take time to learn more about this subject.

Currently, there are no formally approved treatments for this disease. At the moment there are more than 4.7 million confirmed cases. The U.S. has the largest number of confirmed cases. The U.S. officials stated that it would at least 12 to 18 months to produce the vaccine.

Notably, Moderna is not the only company that wants to produce the vaccine. There are more than 100 vaccines are under development in different parts of the world. This information comes from the World Health Organization. Moreover, at least eight vaccines are in human trials.

However, Moderna is the first company to release data on a human trial testing a coronavirus vaccine. Moreover, the company works with the National Institutes of Health to develop a vaccine.

Importantly, Moderna expects to begin a phase 3 trial in July. Also, if the vaccine proves to be effective and safe to use, it would take less than one year before it will become available to the public. Hopefully, companies are working hard to create an effective vaccine.